DIVIS LABORATORIES 2020-21 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES 2020-21 Annual Report Analysis
Thu, 12 Aug

DIVIS LABORATORIES has announced its results for the year ended March 2021. Let us have a look at the detailed performance review of the company during FY20-21.

DIVIS LABORATORIES Income Statement Analysis

  • Operating income during the year rose 29.2% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 56.9% YoY during the fiscal. Operating profit margins witnessed a fall and down at 41.1% in FY21 as against 33.8% in FY20.
  • Depreciation charges increased by 37.2% and finance costs decreased by 70.6% YoY, respectively.
  • Other income declined by 67.0% YoY.
  • Net profit for the year grew by 44.2% YoY.
  • Net profit margins during the year grew from 24.7% in FY20 to 28.2% in FY21.

DIVIS LABORATORIES Income Statement 2020-21

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Net Sales Rs m 53,944 69,694 29.2%
Other income Rs m 1,896 626 -67.0%
Total Revenues Rs m 55,841 70,320 25.9%
Gross profit Rs m 18,232 28,612 56.9%
Depreciation Rs m 1,862 2,556 37.2%
Interest Rs m 71 21 -70.6%
Profit before tax Rs m 18,195 26,660 46.5%
Tax Rs m 4,429 6,818 53.9%
Profit after tax Rs m 13,765 19,843 44.2%
Gross profit margin % 33.8 41.1
Effective tax rate % 24.3 25.6
Net profit margin % 24.7 28.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



EV Stocks: Make a Fortune from Automobile Sector's Colossal Disruption

DIVIS LABORATORIES Balance Sheet Analysis

  • The company's current liabilities during FY21 down at Rs 17 billion as compared to Rs 18 billion in FY20, thereby witnessing an decrease of -5.1%.
  • Current assets rose 22% and stood at Rs 68 billion, while fixed assets rose 19% and stood at Rs 46 billion in FY21.
  • Overall, the total assets and liabilities for FY21 stood at Rs 114 billion as against Rs 94 billion during FY20, thereby witnessing a growth of 21%.

DIVIS LABORATORIES Balance Sheet as on March 2021

No. of Mths Year Ending 12 Mar-20* 12 Mar-21* % Change
Networth Rs m 73,099 92,946 27.2
 
Current Liabilities Rs m 18,205 17,284 -5.1
Long-term Debt Rs m 0 0 0.0
Total Liabilities Rs m 94,250 113,869 20.8
 
Current assets Rs m 55,735 67,906 21.8
Fixed Assets Rs m 38,515 45,963 19.3
Total Assets Rs m 94,250 113,869 20.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



DIVIS LABORATORIES Cash Flow Statement Analysis

  • DIVIS LABORATORIES's cash flow from operating activities (CFO) during FY21 stood at Rs 19 billion, an improvement of 60.1% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY21 stood at Rs 751 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY21 stood at Rs -349 million, an improvement of 97% on a YoY basis.
  • Overall, net cash flows for the company during FY21 stood at Rs 20 billion from the Rs 411 million net cash flows seen during FY20.

DIVIS LABORATORIES Cash Flow Statement 2020-21

Particulars No. of months 12 12 % Change
Year Ending Mar-20 Mar-21
Cash Flow from Operating Activities Rs m 12,159 19,469 60.1%
Cash Flow from Investing Activities Rs m -835 751 -
Cash Flow from Financing Activities Rs m -10,914 -349 -
Net Cash Flow Rs m 411 19,872 4,740.9%
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for DIVIS LABORATORIES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 74.7, an improvement from the EPS of Rs 51.9 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 4,902.6, stands at 63.5 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 8.2 times, while the price to sales ratio stands at 10.9 times.
  • The company's price to cash flow (P/CF) ratio stood at 58.1 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Sales per share (Unadj.) Rs 203.2 262.5
TTM Earnings per share Rs 51.9 74.7
Diluted earnings per share Rs 51.9 74.7
Price to Cash Flow x 83.3 58.1
TTM P/E ratio x 63.5 63.5
Price / Book Value ratio x 6.8 8.2
Market Cap Rs m 1,301,486 1,301,486
Dividends per share (Unadj.) Rs 16.0 20.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for DIVIS LABORATORIES

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 3.9x during FY21, from 3.1x during FY20. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 1,270.5x during FY21, from 255.8x during FY20. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 21.3% during FY21, from 18.8% during FY21. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 28.7% during FY21, from 25.0% during FY20. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 17.4% during FY21, from 14.7% during FY20. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-20* 12 Mar-21*
Current ratio x 3.1 3.9
Debtors’ Days Days 956 878
Interest coverage x 255.8 1,270.5
Debt to equity ratio x 0.0 0.0
Return on assets % 14.7 17.4
Return on equity % 18.8 21.3
Return on capital employed % 25.0 28.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how DIVIS LABORATORIES has performed over the last 5 years, please visit here.

DIVIS LABORATORIES Share Price Performance

Over the last one year, DIVIS LABORATORIES share price has moved up from Rs 3,118.2 to Rs 4,902.6, registering a gain of Rs 1,784.5 or around 57.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 26,061.6 (up 0.2%). Over the last one year it has moved up from 19,096.0 to 26,061.6, a gain of 6,966 points (up 36.5%).

Overall, the S&P BSE SENSEX is up 43.5% over the year.

(To know more, check out historical annual results for DIVIS LABORATORIES and quarterly results for DIVIS LABORATORIES)

Equitymaster requests your view! Post a comment on "DIVIS LABORATORIES 2020-21 Annual Report Analysis". Click here!

  

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY22); Net Profit Up 13.2% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, DIVIS LABORATORIES has posted a net profit of Rs 6 bn (up 13.2% YoY). Sales on the other hand came in at Rs 20 bn (up 13.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY21); Net Profit Up 29.3% (Quarterly Result Update)

Jun 28, 2021 | Updated on Jun 28, 2021

For the quarter ended March 2021, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 29.3% YoY). Sales on the other hand came in at Rs 18 bn (up 28.7% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Is it Time to Switch from Tata Power to NTPC?(Profit Hunter)

Oct 11, 2021

Given the huge run up in Tata Power, does it make sense to switch to NTPC?

This Proxy EV Stock Just got a Power Crisis Boost(Profit Hunter)

Oct 8, 2021

After months of research, I've come across few stocks that excite me far more than the mainstream electric vehicle companies.

Rs 1 Lakh Invested in These Cryptos at the Start of 2021 Became Rs...(Views On News)

Oct 8, 2021

These cryptos would have multiplied investors' wealth by as much as 10,000% in just nine months.

Top 5 'Digital India' Stocks(Views On News)

Oct 6, 2021

These companies are leading the Government's US$1 tn 'Digital India' initiative.

5 Exciting 'Unlisted' Companies and How to Play Them(Views On News)

Oct 7, 2021

Here's how you can invest in some of the most exciting start-ups of the decade.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS